ABSTRACT
Objective:To evaluate the clinical effect of Chaihu Shugan Powder in the treatment of liver qi and spleen deficiency syndrome on cancer related depression (CRD).Methods:A total of 63 patients with cancer related depression from our hospital during September 2018 to October 2019 were divided into observation group (42 cases) and control group (21 cases) according to the ratio of 2 :1. The observation group was applied with Chaihu Shugan Powder, while the control group was given placebo agent of Chaihu-Shugan with 2% Chaihu-Shugan Powder and 98% dextrin. Both groups were treated continuously for 42 days. We used HAMD24 and Traditional Chinese Medicine (TCM) Symptoms Scale to evaluate both before and after treatment. Results:The total efficiency about depression in the observation group was 71.4% (30/42) while the control group was 14.3% (3/21). The difference was statistically significant ( Z=-4.22, P<0.01). After treatment, The HAMD scales of the observation group was 18.67±3.55 while the control group was 24.71±3.74 ( P<0.05). The total effective rate of TCM syndrome in the observation group was 71.4% (30/42) and that in the control group was 14.3% (3/21). There was significant difference between the two groups ( Z=-4.00, P<0.01). TCM Syndrome Score of observation group was 55.33±17.59 while the control group was 62.04±10.72( t=-2.00, P<0.05). Conclusion:Chaihu Shugan Powder can effectively improve the anxiety and depression of CRD patients with syndrome of stagnation of liver qi and spleen deficiency.
ABSTRACT
@#Post-stroke depression often seriously affects the prognosis and quality of life of patients and many clinical trials had shown that Chai Hu Shu Gan San (柴胡疏肝散) combined with selective serotonin reuptake inhibitors (SSRIs) had good efficacy and minor side effects. We aimed to conduct this metaanalysis to evaluate the efficacy and safety of Chai Hu Shu Gan San as an adjuvant drug for SSRI in treating post-stroke depression. We searched PubMed, EMBASE, Cochrane Library, Wanfang, China Biology Medicine disc (CBM), Chongqing VIP, and CNKI (China National Knowledge Infrastructure) from their date of foundation to December 15, 2018. Literature screening, data extraction and quality assessment were conducted by two authors independently. The data synthesis and analysis were performed by using Review Manager (RevMan) 5.3 software and sensitivity analysis was conducted to assess the robustness of the results. Finally, a total of 22 articles were included. The meta-analysis confirmed the advantages of the combination of SSRI and Chai Hu Shu Gan San, mainly from four aspects: the Hamilton Depression (HAMD) scale score (MD=3.66; 95% DI=2.33-4.98; p<0.001), the Modified Edinburgh Scandinavian Stroke Scale (MESSS) score (MD=4.87; 95% CI=2.32-7.43; p<0.001), the efficacy rate (OR=3.50; 95% CI =2.61-4.69; p<0.001) and the incidence of adverse reactions (OR=0.28; 95% CI=0.17-0.46; p<0.001). No significant publication bias was observed, and sensitivity analysis suggested a good stability of the results. According to the present evidence, we concluded that Chai Hu Shu Gan Sa